James Goodhand

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8671006/publications.pdf

Version: 2024-02-01

201674 214800 3,011 60 27 47 citations h-index g-index papers 65 65 65 3682 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. The Lancet Gastroenterology and Hepatology, 2019, 4, 341-353.	8.1	431
2	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. Gastroenterology, 2020, 158, 189-199.	1.3	249
3	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut, 2021, 70, 1884-1893.	12.1	233
4	Mood disorders in inflammatory bowel disease: Relation to diagnosis, disease activity, perceived stress, and other factors. Inflammatory Bowel Diseases, 2012, 18, 2301-2309.	1.9	183
5	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut, 2021, 70, 865-875.	12.1	153
6	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 2019, 321, 773.	7.4	129
7	Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflammatory Bowel Diseases, 2012, 18, 513-519.	1.9	117
8	Systematic review: Clostridium difficile and inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2011, 33, 428-441.	3.7	102
9	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. The Lancet Gastroenterology and Hepatology, 2022, 7, 342-352.	8.1	100
10	Adolescents with IBD: The importance of structured transition care. Journal of Crohn's and Colitis, 2011, 5, 509-519.	1.3	99
11	Do Antidepressants Influence the Disease Course in Inflammatory Bowel Disease? A Retrospective Case-Matched Observational Study. Inflammatory Bowel Diseases, 2012, 18, 1232-1239.	1.9	99
12	Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn's disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 660-669.	3.7	96
13	Massively parallel variant characterization identifies <i>NUDT15</i> alleles associated with thiopurine toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 5394-5401.	7.1	95
14	Inflammatory bowel disease in young people. Inflammatory Bowel Diseases, 2010, 16, 947-952.	1.9	87
15	Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience. Journal of Crohn's and Colitis, 2020, 14, 1385-1393.	1.3	74
16	Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2013, 38, 1097-1108.	3.7	65
17	Does psychological counseling alter the natural history of inflammatory bowel disease?. Inflammatory Bowel Diseases, 2010, 16, 664-669.	1.9	55
18	Integrated Models of Care in Managing Inflammatory Bowel Disease: A Discussion. Inflammatory Bowel Diseases, 2012, 18, 1582-1587.	1.9	51

#	Article	IF	CITATIONS
19	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications, 2022, 13, 1379.	12.8	48
20	How can we improve models of care in inflammatory bowel disease? An international survey of IBD health professionals. Journal of Crohn's and Colitis, 2014, 8, 1668-1674.	1.3	47
21	Management of stress in inflammatory bowel disease: a therapeutic option?. Expert Review of Gastroenterology and Hepatology, 2009, 3, 661-679.	3.0	46
22	Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. Journal of Crohn's and Colitis, 2022, 16, 389-397.	1.3	39
23	Poster presentations at medical conferences: an effective way of disseminating research?. Clinical Medicine, 2011, 11, 138-141.	1.9	36
24	Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2011, 23, 1029-1035.	1.6	35
25	Genome-Wide Association Study of Microscopic Colitis in the UK Biobank Confirms Immune-Related Pathogenesis. Journal of Crohn's and Colitis, 2019, 13, 1578-1582.	1.3	32
26	Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Alimentary Pharmacology and Therapeutics, 2018, 47, 1103-1116.	3.7	31
27	Application of the WHO fracture risk assessment tool (FRAX) to predict need for DEXA scanning and treatment in patients with inflammatory bowel disease at risk of osteoporosis. Alimentary Pharmacology and Therapeutics, 2011, 33, 551-558.	3.7	27
28	Psychological stress and coping in IBD. Gut, 2008, 57, 1345-1347.	12.1	23
29	Factors Associated With Nonadherence to Thiopurines in Adolescent and Adult Patients With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 685-689.	1.8	21
30	The phenotype and course of inflammatory bowel disease in <scp>UK</scp> patients of <scp>B</scp> angladeshi descent. Alimentary Pharmacology and Therapeutics, 2012, 35, 929-940.	3.7	20
31	Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNF \hat{l} ± therapy. Journal of Crohn's and Colitis, 2013, 7, 412-418.	1.3	20
32	Genetic evidence that higher central adiposity causes gastro-oesophageal reflux disease: a Mendelian randomization study. International Journal of Epidemiology, 2020, 49, 1270-1281.	1.9	20
33	Incidence and prevalence of inflammatory bowel disease in Devon, UK. Frontline Gastroenterology, 2021, 12, 461-470.	1.8	18
34	Factors associated with depression in people with inflammatory bowel disease: The relationship between active disease and biases in neurocognitive processing. Neurogastroenterology and Motility, 2019, 31, e13647.	3.0	14
35	Quality improvement project identifies factors associated with delay in IBD diagnosis. Alimentary Pharmacology and Therapeutics, 2020, 52, 471-480.	3.7	14
36	Oral Iron Treatment Response and Predictors in Anaemic Adolescents and Adults with IBD: A Prospective Controlled Open-Label Trial. Journal of Crohn's and Colitis, 2016, 11, jjw208.	1.3	13

#	Article	IF	Citations
37	Tobacco dependence and awareness of health risks of smoking in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2011, 23, 90-94.	1.6	12
38	Do Children With IBD Really Respond Better Than Adults to Thiopurines?. Journal of Pediatric Gastroenterology and Nutrition, 2011, 52, 702-707.	1.8	10
39	Validating the positivity thresholds of drugâ€tolerant antiâ€infliximab and antiâ€adalimumab antibody assays. Alimentary Pharmacology and Therapeutics, 2021, 53, 128-137.	3.7	9
40	Editorial: which iron preparation for patients with IBD?. Alimentary Pharmacology and Therapeutics, 2017, 46, 194-195.	3.7	6
41	Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2021, 53, 291-301.	3.7	5
42	Understanding <scp>antiâ€TNF</scp> treatment failure: does serum triiodothyronineâ€toâ€thyroxine (<scp>T3</scp> / <scp>T4</scp>) ratio predict therapeutic outcome to <scp>antiâ€TNF</scp> therapies in biologicâ€naĀ ve patients with active luminal Crohn's disease?. Alimentary Pharmacology and Therapeutics, 2022, 56, 783-793.	3.7	5
43	Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. Archives of Disease in Childhood, 2020, 105, 957-963.	1.9	4
44	DOP28 Understanding the molecular mechanisms of anti-TNF treatment failure in patients with Crohnâ \in TM s disease: A pilot serum proteomic analysis of the PANTS cohort. Journal of Crohn's and Colitis, 2020, 14, S067-S068.	1.3	3
45	The dangers of living in a tent in London. BMJ Case Reports, 2014, 2014, bcr2013201654-bcr2013201654.	0.5	3
46	Haemosuccus pancreaticus. BMJ: British Medical Journal, 2017, , i6446.	2.3	2
47	OFR-8 Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. , 2021, , .		2
48	Anxiety and Psychological Stress in Acute Severe Ulcerative Colitis: Prevalence and Effect on Outcome. Gastroenterology, 2011, 140, S-60-S-61.	1.3	1
49	Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for rollâ€out?. Alimentary Pharmacology and Therapeutics, 2020, 52, 1076-1077.	3.7	1
50	Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel diseaseâ€"getting to the root. Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 337-338.	3.7	1
51	PTU-163 Depression and carcinoid syndrome: is there any relationship? A cross-sectional study. Gut, 2012, 61, A252.1-A252.	12.1	0
52	Weight loss and lumbosacral back pain in a 79-year-old Indian man. Gut, 2013, 62, 1504-1504.	12.1	0
53	PTU-010 $\hat{a}\in$ Prevalence and phenotype of IBD across primary and secondary care: implications for colorectal cancer surveillance. , 2018, , .		0
54	PWE-010â€Introduction of a primary care dietetics service for functional gut disorders. , 2019, , .		0

#	Article	IF	CITATIONS
55	PTU-108â \in Prospective cohort to identify factors associated with diagnostic delay in patients with inflammatory bowel disease. , 2019, , .		0
56	Jejunal perforation and central retinal vein occlusion in a 55-year-old European man. Gut, 2020, 69, 73-111.	12.1	0
57	DOP69 Tofacitinib in ulcerative colitis: Early â€~real-world' experience from four UK tertiary centres. Journal of Crohn's and Colitis, 2020, 14, S106-S106.	1.3	O
58	P92â€Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multi-centre UK experience., 2021,,.		0
59	P387 Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic. Journal of Crohn's and Colitis, 2021, 15, S398-S399.	1.3	O
60	P196 Pre-treatment antibodies to infliximab and adalimumab are common but are not associated with anti-TNF treatment failure. Journal of Crohn's and Colitis, 2022, 16, i256-i256.	1.3	0